Get email alerts on the Pharmacy topic
No spam. Unsubscribe anytime.
Anti‑obesity drugs drive pharmacy spending in State plan, Capital Rx reports
Summary
Capital Rx told the commission that anti‑obesity agents were the largest pharmacy spend category in Q1 2026 (~$5.5M), and that the top five drugs by plan spend included Zepbound, Wegovy and Mounjaro; Capital Rx postponed the remainder of its presentation to July.
Capital Rx presented quarter‑one pharmacy utilization for the State of Maine plan, reporting plan pay of $22,355,382 and patient pay of $1,393,382 across 70,782 claims (average gross cost per claim $335.52). Capital Rx said plan spend by drug classification was about $986,788 for generics, $12,073,888 for brand drugs, and $9,294,706 for specialty drugs.
Capital Rx highlighted anti‑obesity agents as the top drug classification by plan spend at $5,499,967. The top five drugs by plan spend were identified as Zepbound, Wegovy, Mounjaro, Trikafta and Dupixent. Commission members noted time constraints: because the commission retreat began at 9:30 a.m., Capital Rx postponed the remainder of its presentation to the July meeting.
Management Member Olivia Alford asked whether patient‑pay figures could also be shown as a percentage; Capital Rx responded that it will include that calculation in future reports. No policy action was taken; the item was presented for informational review and will continue on the July agenda.
AI generated
The text on this page is AI generated. Summaries, highlights, analysis, and video transcripts are all produced from the original source material.
AI can make mistakes, so if you spot one, and we will fix it for everyone.
Note: the source content is unaltered by us. Any content source we link to, be it a video, an audio recording, or a document, is presented exactly as its publisher released it. That publisher is usually a government body, sometimes an individual official or another organisation.
